Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases.
Ontology highlight
ABSTRACT: Brain metastases (BMs) are the most common type of brain tumor, and the incidence among breast cancer (BC) patients has been steadily increasing over the past two decades. Indeed, ~ 30% of all patients with metastatic BC will develop BMs, and due to few effective treatments, many will succumb to the disease within a year. Historically, patients with BMs have been largely excluded from clinical trials investigating systemic therapies including immunotherapies (ITs) due to limited brain penetration of systemically administered drugs combined with previous assumptions that BMs are poorly immunogenic. It is now understood that the central nervous system (CNS) is an immunologically distinct site and there is increasing evidence that enhancing immune responses to BCBMs will improve patient outco
SUBMITTER: Carney CP
PROVIDER: S-EPMC8568876 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA